[en] Parathyroid hormone (PTH) measurement in serum or plasma is a necessary tool for the exploration of calcium/phosphate disorders, and is widely used as a surrogate marker to assess skeletal and mineral disorders associated with chronic kidney disease (CKD), referred to as CKD-bone mineral disorders (CKD-MBD). CKD currently affects >10% of the adult population in the United States and represents a major health issue worldwide. Disturbances in mineral metabolism and fractures in CKD patients are associated with increased morbidity and mortality. Appropriate identification and management of CKD-MBD is therefore critical to improving clinical outcome. Recent increases in understanding of the complex pathophysiology of CKD, which involves calcium, phosphate and magnesium balance, and is also influenced by vitamin D status and fibroblast growth factor (FGF)-23 production, should facilitate such improvement. Development of evidence-based recommendations about how best to use PTH is limited by considerable method-related variation in results, of up to 5-fold, as well as by lack of clarity about which PTH metabolites these methods recognise. This makes it difficult to compare PTH results from different studies and to develop common reference intervals and/or decision levels for treatment. The implications of these method-related differences for current clinical practice are reviewed here. Work being undertaken by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) to improve the comparability of PTH measurements worldwide is also described.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Sturgeon, Catharine M.
Sprague, Stuart
Almond, Alison
Cavalier, Etienne ; Université de Liège > Département de pharmacie > Chimie médicale
Fraser, William D.
Algeciras-Schimnich, Alicia
Singh, Ravinder
Souberbielle, Jean-Claude
Vesper, Hubert W.
Language :
English
Title :
Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH.
[1] Souberbielle, J.C., Brazier, F., Pikkety, M., Cormier, C., Minisola, S., Cavalier, E., How the reference values for serum parathyroid hormone concentration are (or should be) established?. J. Endocrinol. Invest., 2016, 10.1007/s40618-016-0553-2 (Epub ahead of print).
[3] Moe, S., Drueke, T., Cunningham, J., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 69 (2006), 1945–1953.
[5] Levin, A., Bakris, G.L., Molitch, M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71 (2007), 31–38.
[6] Gal-Moscovici, A., Sprague, S.M., Use of vitamin D in chronic kidney disease patients. Kidney Int. 78 (2010), 146–151.
[7] Sturgeon, C.M., Sprague, S.M., Metcalfe, W., Variation in parathyroid hormone immunoassay results–a critical governance issue in the management of chronic kidney disease. Nephrol. Dial. Transplant. 26 (2011), 3440–3445.
[8] Cavalier, E., Plebani, M., Delanaye, P., Souberbielle, J.C., Considerations in parathyroid hormone testing. Clin. Chem. Lab. Med. 53 (2015), 1913–1919.
[9] Cole, D.E., Webb, S., Chan, P.C., Update on parathyroid hormone: new tests and new challenges for external quality assessment. Clin. Biochem. 40 (2007), 585–590.
[10] Sprague, S.M., Moe, S.M., The case for routine parathyroid hormone monitoring. Clin. J. Am. Soc. Nephrol. 8 (2013), 313–318.
[11] Garrett, G., Sardiwal, S., Lamb, E.J., Goldsmith, D.J., PTH–a particularly tricky hormone: why measure it at all in kidney patients?. Clin. J. Am. Soc. Nephrol. 8 (2013), 299–312.
[12] Almond, A., Ellis, A.R., Walker, S.W., Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann. Clin. Biochem. 49 (2012), 63–67.
[13] KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 2009, S1–130.
[14] Sprague, S.M., Moe, S.M., Rebuttal: PTH – a particularly tricky hormone: why measure it at all in kidney patients?. Clin. J. Am. Soc. Nephrol., 8, 2013, 321.
[15] Sprague, S.M., Bellorin-Font, E., Jorgetti, V., et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am. J. Kidney Dis. 67 (2016), 559–566.
[16] Uhlig, K., Berns, J.S., Kestenbaum, B., et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am. J. Kidney Dis. 55 (2010), 773–799.
[17] Greg Miller, W., Myers, G.L., Lou Gantzer, M., et al. Roadmap for harmonization of clinical laboratory measurement procedures. Clin. Chem. 57 (2011), 1108–1117.
[18] Sturgeon, C.M., Falconer, H., Al-Sadie, R., UK NEQAS [Edinburgh] Annual Review - Data for 2015. 2016.
[19] Sturgeon, C.M., Common decision limits – the need for harmonised immunoassays. Clin. Chim. Acta 432 (2014), 122–126.
[20] Souberbielle, J.C., Boutten, A., Carlier, M.C., et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 70 (2006), 345–350.
[21] Sturgeon, C.M., External quality assessment of hormone determinations. Best Pract. Res. Clin. Endocrinol. Metab. 27 (2013), 803–822.
[22] WHO, International Standard for Parathyroid Hormone 1–84 (Version 9). 2010.
[24] Hanon, E.A., Sturgeon, C.M., Lamb, E.J., Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin. Chem. Lab. Med. 51 (2013), 1925–1941.
[25] Yan, R., Lou, A., Watts, G., et al. Comparison of Becton Dickinson Vacutainer rapid serum tube with the serum separator tube for routine chemistry and immunoassay tests. J. Clin. Pathol. 67 (2014), 599–604.
[27] Van Houcke, S.K., Thienpont, L.M., “Good samples make good assays” - the problem of sourcing clinical samples for a standardization project. Clin. Chem. Lab. Med. 51 (2013), 967–972.
[28] Bilezikian, J.P., Brandi, M.L., Eastell, R., et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J. Clin. Endocrinol. Metab. 99 (2014), 3561–3569.
[29] Ennis, J.L., Worcester, E.M., Coe, F.L., Sprague, S.M., Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J. Nephrol. 29 (2016), 63–70.
[30] Sprague, S.M., Silva, A.L., Al-Saghir, F., et al. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am. J. Nephrol. 40 (2014), 535–545.
[31] Eastell, R., Arnold, A., Brandi, M.L., et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94 (2009), 340–350.
[32] Binkley, N., Sempos, C.T., Standardizing vitamin D assays: the way forward. J. Bone Miner. Res. 29 (2014), 1709–1714.
[33] Couchman, L., Taylor, D.R., Krastins, B., Lopez, M.F., Moniz, C.F., LC-MS candidate reference methods for the harmonisation of parathyroid hormone (PTH) measurement: a review of recent developments and future considerations. Clin. Chem. Lab. Med. 52 (2014), 1251–1263.
[34] Kumar, V., Barnidge, D.R., Chen, L.S., et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin. Chem. 56 (2010), 306–313.
[35] Lopez, M.F., Rezai, T., Sarracino, D.A., et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 56 (2010), 281–290.
